Tech Company Financing Transactions
D3 Bio Funding Round
D3 Bio, based in Wuxi, JiangSu, secured $108 million from IDG Capital Partners, Medicxi Ventures and Sequoia Capital China.
Transaction Overview
Company Name
Announced On
12/10/2025
Transaction Type
Venture Equity
Amount
$108,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to support the planned global Phase III pivotal program for its lead asset, elisrasib (D3S-001).
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
88 MeiLiang Road; MaShan Street; BinHu District 324
Wuxi, JiangSu, 214000
China
Wuxi, JiangSu, 214000
China
Phone
Undisclosed
Website
Email Address
Overview
D3 Bio is a globally focused biotechnology company focusing on developing and registration of innovative medicines in oncology and immunology. At D3 Bio, our new medicine development approach is fundamentally differentiated. We do not just only start with science in the lab. First, we start from pinpointing the greatest unmet patient and market needs -- where existing standard-of-care approaches yield unsatisfactory clinical outcomes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
George Chen
Chief Financial Officer
John Jin
Browse more venture capital transactions:
Prev: 12/10/2025: Boom Supersonic venture capital transaction
Next: 12/10/2025: Allonnia venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on all VC transactions involving tech companies. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs